We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma.
- Authors
Lee, Hyung Keun; Kim, So Young; Chung, Soo-Hyun; Choi, Bongkun; Kim, Ji-Eun; Yoon, Dohee; Jang, Sung Ill; Yeo, Areum; Kang, Hyun Goo; Lee, Jusung; Choi, Yoon Ha; Park, Joon Seong; Sung, Yoolim; Kim, Jong Kyoung; Chang, Eun-Ju; Lee, Dong Ki
- Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor survival rate, largely due to the lack of early diagnosis. Although myeloid cells are crucial in the tumour microenvironment, whether their specific subset can be a biomarker of PDAC progression is unclear. Methods: We analysed IL-22 receptor expression in PDAC and peripheral blood. Additionally, we analysed gene expression profiles of IL-10R2+/IL-22R1+ myeloid cells and the presence of these cells using single-cell RNA sequencing and murine orthotropic PDAC models, respectively, followed by examining the immunosuppressive function of IL-10R2+/IL-22R1+ myeloid cells. Finally, the correlation between IL-10R2 expression and PDAC progression was evaluated. Results: IL-10R2+/IL-22R1+ myeloid cells were present in PDAC and peripheral blood. Blood IL-10R2+ myeloid cells displayed a gene expression signature associated with tumour-educated circulating monocytes. IL-10R2+/IL-22R1+ myeloid cells from human myeloid cell culture inhibited T cell proliferation. By mouse models for PDAC, we found a positive correlation between pancreatic tumour growth and increased blood IL-10R2+/IL-22R1+ myeloid cells. IL-10R2+/IL-22R1+ myeloid cells from an early phase of the PDAC model suppressed T cell proliferation and cytotoxicity. IL-10R2+ myeloid cells indicated tumour recurrence 130 days sooner than CA19-9 in post-pancreatectomy patients. Conclusions: IL-10R2+/IL-22R1+ myeloid cells in the peripheral blood might be an early marker of PDAC prognosis.
- Publication
British Journal of Cancer, 2024, Vol 130, Issue 12, p1979
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/s41416-024-02676-w